Molecule
Glycopyrronium is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. It is available as cloths for topical use. MedsAcross supplies Glycopyrronium for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.
Source: US FDA prescribing information
Glycopyrronium is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands, reducing sweating.
Source: US FDA prescribing information
For topical use only. Qbrexza is for topical use in the underarm area only and not for use in other body areas. Qbrexza is administered by a single-use pre-moistened cloth packaged in individual pouches. Qbrexza should be applied to clean dry skin on the underarm areas only. Qbrexza should not be used more frequently than once every 24 hours. Tear open the pouch and pull out the cloth, unfold the cloth, and wipe it across one entire underarm once. Using the same cloth, wipe the other underarm once. A single cloth should be used to apply Qbrexza to both underarms. After applying Qbrexza, discard the cloth in the household trash out of reach of children and others. Wash hands immediately with soap and water after applying and discarding the Qbrexza cloth. Qbrexza may cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.
Source: US FDA prescribing information
Qbrexza is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of Qbrexza (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).
Source: US FDA prescribing information
New or worsening urinary retention: Use with caution in patients with a history of documented urinary retention. Control of body temperature: In the presence of high ambient temperature, heat illness may occur, avoid use if patients develop generalized lack of sweating when exposed to hot or very warm environmental temperatures. Operating machinery or an automobile: Transient blurred vision may occur with use of Qbrexza. If blurred vision occurs, discontinue use of Qbrexza until symptoms resolve, avoid operating a motor vehicle or other machinery until symptoms resolve.
Source: US FDA prescribing information
The following adverse reactions are described in greater detail in other sections • New or Worsening Urinary Retention Most common adverse reactions (incidence ≥2%) are dry mouth, mydriasis, oropharyngeal pain, headache, urinary hesitation, vision blurred, nasal dryness, dry throat, dry eye, dry skin, constipation. Local skin reactions, including erythema, burning/stinging and pruritus were also common (>5%).
Source: US FDA prescribing information
Coadministration of Qbrexza with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of Qbrexza with other anticholinergic-containing drugs.
Source: US FDA prescribing information
Store at room temperature 20° - 25°C (68° - 77°F), excursions permitted to 15° - 30°C (59° - 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Glycopyrronium, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Qbrexza 2.4 g/100 g clothTopical | Journey Medical | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Glycopyrronium in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Glycopyrronium and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Glycopyrronium, including Qbrexza.
Yes. The US FDA first approved Glycopyrronium on 28 June 2018, according to Drugs@FDA.
Yes. Glycopyrronium has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Glycopyrronium is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Glycopyrronium is classified under ATC code A03AB02 (Glycopyrrolate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.